Evidence map›Paper›PMID 36894959›Full record

Trial reportBMC research notes2023

Randomized clinical trial with fractional CO

Hakayna Calegaro Salgado, Denise Gasparetti Drumond, Gabriel Duque Pannain, Louise Gracielle de Melo E Costa, Fernanda Souza Sampaio, Isabel Cristina Gonçalves Leite

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC research notes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Retrospective Study on COThe journal of obstetrics and gynaecology research · 2025
    Article
  9. Efficacy of Fractional COLife (Basel, Switzerland) · 2024
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hakayna Calegaro SalgadoFederal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil.ORCID http://orcid.org/0000-0003-3883-1531
Denise Gasparetti DrumondDepartment of Surgery Medical School, Federal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil.ORCID http://orcid.org/0000-0003-2009-7527
Gabriel Duque PannainMedical Residency, Institute of Medical Assistence to State Public Servants, São Paulo, SP, 04039-000, Brazil.ORCID http://orcid.org/0000-0002-5164-3554
Louise Gracielle de Melo E CostaPathology Department, Federal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil.ORCID http://orcid.org/0000-0001-5854-0411
Fernanda Souza SampaioGynecology Service, University Hospital of the Federal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil.ORCID http://orcid.org/0000-0001-8001-5787
Isabel Cristina Gonçalves LeitePublic Health Department, Federal University of Juiz de Fora, Juiz de Fora, MG, 36036-110, Brazil. isabel.leite@ufjf.edu.br.ORCID http://orcid.org/0000-0003-1258-7331
Universidade Federal de Juiz de Fora · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe main objective of the study was to describe and compare the feasibility of using fractional CO

resultsThe clinical/anatomical characteristics of the vulva did not differ between the treatment groups, as much before as after its performance. There was no statistically significant difference between the treatments performed regarding the impact on the life quality of the patients. A higher satisfaction degree with the treatment was obtained with the patients in the Laser group in the third month of evaluation. Laser therapy also revealed higher occurrence of telangiectasia after treatment completion. Fractional CO2 laser has proven to be well accepted and is a promising therapeutic option. Registration number and name of trial registry The institutional review board status was approved by the Research Ethics Committee of HU/ UFJF under advisory number 2881073 and registered in the Brazilian Clinical Trials, with consent under registration RBR-4p9s5y. Access link: https://ensaiosclinicos.gov.br/rg/RBR-4p9s5y.

Indexed as

Lasers, GasVulvar Lichen SclerosusCarbon DioxideClobetasolFeasibility StudiesFemaleGlucocorticoidsHumansQuality of LifeCarbon DioxideClobetasolGlucocorticoidsClobetasolLaser therapyVulva diseasesVulvar Sclerosus Lichen

Identifiers

PMID36894959
PMCPMC9999649
OpenAlexW4323807083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.